Overview
Location
United States, Maryland, Baltimore
Employees
51-200
Founded date
2013
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 11, 2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| Jan 8, 2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| Jan 8, 2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| Oct 28, 2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| Oct 27, 2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| Oct 27, 2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| Sep 9, 2024 | Стартап в сфере клеточной терапии ArsenalBio привлек $325 млн | В раунде финансирования Arsenal Biosciences приняли участие новые инвесторы ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (венчурное подразделение NVIDIA), Luma Group, фонды, консультируемые T. Rowe Price... |
| Sep 4, 2024 | ArsenalBio Raises $325M in Series C Funding | ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding. The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, fu... |
| Sep 4, 2024 | ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs | Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round. This fund... |
Show more
Reviews 0
FAQ about Rock Springs Capital
When was Rock Springs Capital founded?
Rock Springs Capital was founded in 2013.
What has the press written about Rock Springs Capital?
Parsers VC has collected 25 articles mentioning Rock Springs Capital, among them “Parabilis Medicines Secures $305 Million for Cancer Drug Revolution” (Jan 11, 2026) and “Parabilis Medicines Raises $305M Series F Funding” (Jan 8, 2026).
Is Rock Springs Capital still active?
Rock Springs Capital is probably closed: its latest activity on Parsers VC dates from Aug 18, 2026.